# Oral Vancomycin for Preventing Clostridium Difficile Recurrence

> **NCT03200093** · PHASE4 · TERMINATED · sponsor: **Rochester General Hospital** · enrollment: 65 (actual)

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **DRUG:** Oral Vancomycin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03200093
- **Lead sponsor:** Rochester General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-08
- **Primary completion:** 2021-04-22
- **Final completion:** 2021-04-22
- **Target enrollment:** 65 (ACTUAL)
- **Why stopped:** Low recruitment due to few eligible participants.
- **Last updated:** 2021-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03200093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03200093, "Oral Vancomycin for Preventing Clostridium Difficile Recurrence". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03200093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*